Shares of Tectonic Therapeutic Inc. (NASDAQ: TECX) plunged 5.44% on Wednesday morning after the clinical-stage biotech company reported a wider-than-expected loss for the third quarter of 2024.
Tectonic reported an adjusted loss per share of $1.20 for Q3, missing consensus analyst estimates of $0.82 loss per share. The company's GAAP net loss of $17.72 million was also larger than the prior year's Q3 loss of $5.28 per share.
The disappointing results appear to have triggered a sell-off in Tectonic's stock, which had rallied 48% over the past quarter and nearly 175% year-to-date heading into the earnings release. With no revenue yet as a development-stage biotech firm, Tectonic's valuation is highly sensitive to changes in cash burn rates and missed earnings expectations.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。